ArriVent BioPharma, Inc. Common Stock (AVBP) NASDAQ
26.73
-0.27(-1.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
26.73
-0.27(-1.00%)
Currency In USD
Address
18 Campus Boulevard
Newtown Square, 19073
United States of America (the)
Phone
628-277-4836
Website
Sector
Healthcare
Industry
Biotechnology
Employees
52
First IPO Date
January 26, 2024
| Name | Title | Pay | Year Born |
| Zhengbin Yao | Co-Founder, Chairman, President & Chief Executive Officer | 968,667 | 1966 |
| Robin LaChapelle | Co-Founder & Chief Operating Officer | 586,453 | 1973 |
| Winston Kung | Chief Financial Officer & Treasurer | 752,704 | 1976 |
| Stuart Lutzker | Co-Founder, President of Research & Development and Director | 777,353 | 1961 |
| James Paul Kastenmayer | General Counsel & Secretary | 0 | 1972 |
| Brent S. Rice | Chief Commercial Officer | 0 | 1966 |
| Yang Wang | Chief Technology Officer | 0 | N/A |
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.